You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Medtronic
AstraZeneca
Merck
Harvard Business School

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Claims for Patent: 5,663,483

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,663,483
Title: Transgenic mice expressing human cholesterol 7.alpha.hydroxylase
Abstract:Genomic DNA of cholesterol 7.alpha.-hydroxylase and a minigene are disclosed. The minigene is used for making a transgenic animal that produces functionally active cholesterol 7.alpha.-hydroxylase and functions as a disease model. A cholesterol 7.alpha.-hydroxylase promoter region and reporter gene construct is provided, as well as a transgenic animal that expresses the promoter/reporter gene.
Inventor(s): Chiang; John Young Ling (Stow, OH)
Assignee: Northeastern Ohio Universities College of Medicine (Rootstown, OH)
Application Number:08/361,458
Patent Claims:1. A method of making a transgenic mouse that expresses human cholesterol 7.alpha.-hydroxylase (CYP7) in liver tissue in an amount higher than that of normal murine CYP7 expression in an unmodified, non-transgenic mouse comprising the steps of:

(A) microinjecting a fertilized oocyte of a mouse with a human CYP7 minigene construct comprising a promoter region operably linked to CYP7 nucleotide fragments comprising exon I, intron I, exon II, intron II, exon III, exon IV, exon V, and exon VI, and

(B) detecting expression of human cholesterol 7.alpha.-hydroxylase (CYP7) in liver tissue of a mouse generated from said fertilized oocyte.

2. A method according to claim 1, wherein said minigene construct further comprises a partial intron IV.

3. A method according to claim 2, wherein said minigene construct further comprises intron V.

4. A method according to claim 1, wherein said promoter region of said minigene construct is a promoter sequence obtained from a 5.5 kb sequenced fragment of .lambda.HG7.alpha.26 (ATCC 75534).

5. A transgenic mouse made by the method of claim 1 that expresses human cholesterol 7.alpha.-hydroxylase (CYP7) in liver tissue in an amount higher than that of normal murine CYP7 expression in an unmodified, non-transgenic mouse.

6. A progeny of the mouse of claim 5 that expresses human cholesterol 7.alpha.-hydroxylase (CYP7) in liver tissue in an amount higher than that of normal murine CYP7 expression in an unmodified, non-transgenic mouse.

7. A germ cell of the mouse of claim 5 that is capable of producing a transgenic mouse that expressed human cholesterol 7.alpha.-hydroxlase (CYP7) in liver tissue in an amount higher than that of normal murine CYP7 expression in an unmodified, non-transgenic mouse.

8. A transgenic mouse which expresses human cholesterol 7.alpha.-hydroxylase (CYP7), wherein said human CYP7 is expressed in liver tissue in an amount higher than that of normal murine CYP7 expression in an unmodified, non-transgenic mouse.

9. A progeny of the mouse of claim 8 that expresses human cholesterol 7.alpha.-hydroxylase (CYP7) in liver tissue in an amount higher than that of normal murine CYP7 expression in an unmodified, non-transgenic mouse.

10. A germ cell of the mouse of claim 8 that is capable of producing a transgenic mouse that expresses human cholesterol 7.alpha.-hydroxylase (CYP7) in liver tissue in an amount higher than that of normal murine CYP7 expression in an unmodified, non-transgenic mouse.

Details for Patent 5,663,483

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Northeastern Ohio Universities College of Medicine (Rootstown, OH) 2014-09-02 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Northeastern Ohio Universities College of Medicine (Rootstown, OH) 2014-09-02 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Northeastern Ohio Universities College of Medicine (Rootstown, OH) 2014-09-02 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Harvard Business School
McKesson
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.